Explore Cardiff University    Home   About   Education   Research   News   Events   A-Z
Cardiff University
Innovation Network

Innovation Prize Winner in Hepatitis Drug Deal

Monday 16 January 2012
Bristol-Myers Squibb - an American pharmaceutical giant - will purchase US biotech company Inhibitex, in a $2.5Bn (£1.6bn) deal which includes the promising new anti-hepatitis C drug INX-189, first designed and prepared in Cardiff University.
The buy-out means Bristol-Myers will continue the development of INX-189, a Hepatitis C drug which is currently in Phase II trials and has shown potent anti-viral activity and a high barrier to resistance.

The drug was first created by Professor Chris McGuigan at the Welsh School of Pharmacy and Pharmaceutical Sciences.

The collaboration between the Welsh School of Pharmacy and Inhibitex Inc was awarded the
Innovation Prize at the 2008 the Cardiff University Innovation Awards.


Further Information
Cardiff University announcement
2008 Innovation Prize & Video

Go back to view all news:
Back to list of news
Follow us on Facebook    Follow us on Twitter    Share in our video selection on Youtube    Join our Linked In Group
© Cardiff University    Accessibility   Feedback   Cookies   Privacy Policy   Terms of Use   A-Z